6,624 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Acquired by Headlands Technologies LLC

Headlands Technologies LLC purchased a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 6,624 shares of the company’s stock, valued at approximately $162,000.

A number of other large investors have also bought and sold shares of MYGN. Glenview Capital Management LLC grew its position in Myriad Genetics by 39.6% during the 4th quarter. Glenview Capital Management LLC now owns 5,283,982 shares of the company’s stock worth $101,135,000 after acquiring an additional 1,500,000 shares during the last quarter. Wellington Management Group LLP grew its position in Myriad Genetics by 20.4% during the 4th quarter. Wellington Management Group LLP now owns 7,219,706 shares of the company’s stock worth $138,185,000 after acquiring an additional 1,223,446 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Myriad Genetics by 8.6% during the 4th quarter. Vanguard Group Inc. now owns 9,954,233 shares of the company’s stock worth $190,524,000 after buying an additional 789,496 shares in the last quarter. Sei Investments Co. lifted its holdings in Myriad Genetics by 41.9% during the 4th quarter. Sei Investments Co. now owns 2,161,434 shares of the company’s stock worth $41,370,000 after buying an additional 638,147 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Myriad Genetics by 80.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 334,717 shares of the company’s stock worth $7,620,000 after buying an additional 149,234 shares in the last quarter. 99.02% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on MYGN. Jefferies Financial Group reaffirmed an “underperform” rating and set a $20.00 price objective (down previously from $25.00) on shares of Myriad Genetics in a report on Monday, June 3rd. TD Cowen increased their price target on Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Wells Fargo & Company started coverage on Myriad Genetics in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $35.00 price target on the stock. Scotiabank increased their price target on Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a research note on Tuesday, August 13th. Finally, JPMorgan Chase & Co. increased their price target on Myriad Genetics from $17.00 to $20.00 and gave the company an “underweight” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.60.

Myriad Genetics Price Performance

MYGN opened at $27.59 on Friday. The company has a quick ratio of 1.78, a current ratio of 1.96 and a debt-to-equity ratio of 0.05. Myriad Genetics, Inc. has a 12 month low of $13.82 and a 12 month high of $29.08. The company has a fifty day simple moving average of $27.23 and a 200 day simple moving average of $23.90. The stock has a market cap of $2.51 billion, a P/E ratio of -9.78 and a beta of 1.92.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, August 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. The firm had revenue of $211.50 million during the quarter, compared to analysts’ expectations of $206.44 million. Myriad Genetics had a negative return on equity of 5.64% and a negative net margin of 19.35%. The company’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.21) EPS. On average, research analysts expect that Myriad Genetics, Inc. will post -0.34 EPS for the current year.

Insiders Place Their Bets

In other Myriad Genetics news, Director Colleen F. Reitan sold 46,012 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the completion of the transaction, the director now owns 42,533 shares in the company, valued at approximately $1,188,797.35. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Heinrich Dreismann sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $27.05, for a total value of $270,500.00. Following the completion of the transaction, the director now owns 121,648 shares in the company, valued at approximately $3,290,578.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Colleen F. Reitan sold 46,012 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total value of $1,286,035.40. Following the completion of the transaction, the director now owns 42,533 shares of the company’s stock, valued at approximately $1,188,797.35. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.